Zenith Capital Corp
OTC:ZHCLF
Zenith Capital Corp
Zenith Capital Corp. is a biotechnology investment company, which engages on the discovery and development of novel therapeutics. The company is headquartered in Calgary, Alberta. The company went IPO on 2020-03-06. The Company’s subsidiary, Zenith Epigenetics Ltd. is a clinical stage biotechnology company, which is focused on the discovery and development of therapeutics for the treatment of cancer and other disorders with unmet medical need. Zenith Epigenetics Ltd. is developing various combinations of extra terminal domain (BET) inhibitors with other targeted agents. The lead compound, ZEN-3694, is in development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer. In collaboration with Pfizer, the Company is advancing ZEN-3694 in combination with talazoparib in a Phase II study in triple negative breast cancer (TNBC) patients, which do not have a hereditary BRCA1/2 mutation. This is expected to greatly expand the patient population addressed by poly adenosine diphosphate-ribose polymerase (PARP) inhibitors.
Zenith Capital Corp. is a biotechnology investment company, which engages on the discovery and development of novel therapeutics. The company is headquartered in Calgary, Alberta. The company went IPO on 2020-03-06. The Company’s subsidiary, Zenith Epigenetics Ltd. is a clinical stage biotechnology company, which is focused on the discovery and development of therapeutics for the treatment of cancer and other disorders with unmet medical need. Zenith Epigenetics Ltd. is developing various combinations of extra terminal domain (BET) inhibitors with other targeted agents. The lead compound, ZEN-3694, is in development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer. In collaboration with Pfizer, the Company is advancing ZEN-3694 in combination with talazoparib in a Phase II study in triple negative breast cancer (TNBC) patients, which do not have a hereditary BRCA1/2 mutation. This is expected to greatly expand the patient population addressed by poly adenosine diphosphate-ribose polymerase (PARP) inhibitors.
